NCT03029988View on ClinicalTrials.gov

An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

September 24, 2018

Study Completion Date

September 24, 2018

Conditions
Liver MetastasesColorectal Carcinoma
Interventions
DRUG

Tilmanocept (Technetium Tc 99m tilmanocept Injection)

Drug: Technetium Tc 99m tilmanocept

PROCEDURE

SPECT/CT Imaging

4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.

Trial Locations (1)

35249

University of Alabama Birmingham, Birmingham

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Navidea Biopharmaceuticals

INDUSTRY